120028-55-9

Basic information

• Product Name: 3-(2-quinazolinylmethoxy)benzenacetonitrile
• Synonyms: 3-(2-quinazolinylmethoxy)benzenacetonitrile
• CAS NO: 120028-55-9
• Molecular Weight: 275.31
• Mol File: 120028-55-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(2-quinazolinylmethoxy)benzenacetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-quinazolinylmethoxy)benzenacetonitrile(120028-55-9)
• EPA Substance Registry System: 3-(2-quinazolinylmethoxy)benzenacetonitrile(120028-55-9)

Safety Data

• Hazardous Substances Data: 120028-55-9(Hazardous Substances Data)

Upstream product

• 253-82-7 quinazoline 
• 25263-44-9 3-Hydroxyphenylacetonitrile 
• 6148-18-1 2-chloromethylquinazoline 

Downstream Products

• 120028-56-0 2-[[3-(1H-tetrazol-5-ylmethyl)phenoxy]methyl]quinazoline 

Relevant articles and documents

Quinoline compounds as antiallergic and antiinflammatory agents

There are disclosed compounds of the formula STR1 wherein R1 is STR2 n is 0-5; R2 is hydrogen, loweralkyl, loweralkoxy, lower alkoxycarbonyl, trifluoromethyl, nitro, cyano or halo; R3 is hydrogen or loweralkyl; R4 hydrogen, lower alkyl, --COOR3 or STR3 R5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or STR4 and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents.

2-(phenoxymethyl)-quinazolines as antiallergic and antiinflammatory agents

There are disclosed compounds of the formula STR1 wherein STR2 R2 is hydrogen, loweralkyl, loweralkoxy, lower alkoxycarbonyl, trifluoromethyl, nitro, cyano or halo; R3 is hydrogen or loweralkyl; R4 is hydrogen, lower alkyl, --COOR3 or STR3 R5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or STR4 and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents.